61494-55-1

Basic information

• Product Name: 2-Chloro-3-pyridineacetic acid
• Synonyms: 2-Chloro-3-pyridineacetic acid;2-CHLORO-PYRIDINE-3-YL-ACETIC ACID;2-Chloropyridine-3-acetic acid;(2-Chloropyridin-3-yl)acetic acid 95+%;3-(Carboxymethyl)-2-chloropyridine;2-(2-chloropyridin-3-yl)acetic acid;(2-CHLORO-PYRIDIN-3-YL)-ACETIC ACID
• CAS NO: 61494-55-1
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 171.58
• Product Categories: pharmacetical
• Mol File: 61494-55-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 203-204 °C(Solv: benzene (71-43-2))
• Boiling Point: 336.6oC at 760 mmHg
• Flash Point: 157.4oC
• Appearance: /
• Density: 1.405g/cm3
• Vapor Pressure: 4.34E-05mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.79±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-3-pyridineacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-pyridineacetic acid(61494-55-1)
• EPA Substance Registry System: 2-Chloro-3-pyridineacetic acid(61494-55-1)

Safety Data

• Hazardous Substances Data: 61494-55-1(Hazardous Substances Data)

Usage

Physical Form

Solid

Uses

2-(2-Chloropyridin-3-yl)acetic Acid can be prepared to use as RORγ agonists for the treatment of cancer.

InChI:InChI=1/C7H6ClNO2/c8-7-5(4-6(10)11)2-1-3-9-7/h1-3H,4H2,(H,10,11)

Upstream product

• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 166770-75-8 (2-chloropyridin-3-yl)methyl methanesulfonate 
• 286836-24-6 (7-bromobenzofuran-5-yl)methanol 
• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 89581-84-0 2-chloro-3-(chloromethyl)pyridine 
• 773837-37-9 sodium cyanide 
• 6959-48-4 3-chloromethylpyridinium chloride 
• 6635-88-7 3-(cyanomethyl)pyridine 1-oxide 
• 6443-85-2 3-pyridinylacetonitrile 

Downstream Products

• 127555-83-3 1-(2,4-Difluoro-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 127555-70-8 1-(4-Chlorophenyl)-1,3-dihydro-2H-pyrrolo[2,3-b]-pyridin-2-one 
• 127555-16-2 1-(4-Methoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 127555-84-4 1-(3,5-Dichloro-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 6419-36-9 3-pyridineacetic acid hydrochloride 
• 1202067-21-7 3-[(2,2-dimethyltetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrol-5-yl)carbonyl]-N-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine 
• 1202067-35-3 (cis-3,4-dihydroxypyrrolidin-1-yl)-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]methanone 
• 1202066-93-0 5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]-3-methyl-hexahydropyrrolo[3,4-d]oxazol-2-one 
• 1202066-95-2 (3aR,6aS)-5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]-tetrahydro[1,3]dioxolo[4,5-c]pyrrol-2-one 
• 1202067-94-4 [(3S,4S)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202067-39-7 [(3R,4S)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202067-89-7 [(3S,4R)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202068-00-5 [2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-[(3S,4S)-3-hydroxy-4-(methylamino)pyrrolidin-1-yl]-methanone 
• 1202067-18-2 [2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-[(4aS,7aR)-hexahydropyrrolo[3,4-b][1,4]oxazin-6-yl]-methanone 

Relevant articles and documents

TOPICAL FORMULATIONS

Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS

Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X1, X2, X3, R1, R2, R2a, R13, Rl3a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

Preparation method of 3-pyridylacetic acid hydrochloride

The invention discloses a preparation method of 3-pyridylacetic acid hydrochloride and belongs to the field of chemistry. A 3-pyridylacetic acid hydrochloride product is prepared from 3-methylpyridine chlorination side product 2-chloro-3-methylpyridine as a raw material through cyanidation, alkaline hydrolysis, hydrogenation reduction and salification. The 3-pyridylacetic acid hydrochloride product has purity of 98.5% or more.